Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter
— Reported $37.9 Million in Revenue from the Delivery of the First BARDA Procurement of NUZYRA
— Received FDA…
